Antigen-specific allogeneic immunotherapy--selective augmentation of GVL effects

Yoshiki Akatsuka

Research output: Contribution to journalReview article

Abstract

Advancement of chemotherapeutic agents and introduction of molecular-targeted therapy have been improving the prognosis of malignant tumors. However, allogeneic hematopoietic cell transplantation (allo-HCT) still remains the sole curative therapy against chemotherapy-resistant hematological malignancies. Once it was found that full engraftment of donor's immune cells could bring sufficient graft-versus-leukemia/lymphoma(GVL)effects, reduced intensity preconditioning regimens that focus only on suppression of the recipient's immune system so as to allow donor graft engraftment have been introduced into clinics. This has expanded the number of patients eligible for allo-HCT, including elderly patients. Nevertheless, overall survival of patients with high-risk malignancies has not been sufficiently improved. Simple enhancement of donor-derived immunity would result in the increased risk of graft-versus-host disease (GVHD). Here, current and future strategies to selectively enhance GVL effects without inducing detrimental GVHD will be discussed in parallel with their background information and basic concepts.

Original languageEnglish
Pages (from-to)713-719
Number of pages7
JournalGan to kagaku ryoho. Cancer & chemotherapy
Volume35
Issue number5
Publication statusPublished - 01-01-2008
Externally publishedYes

Fingerprint

Immunotherapy
Lymphoma
Leukemia
Cell Transplantation
Tissue Donors
Graft vs Host Disease
Transplants
Antigens
Molecular Targeted Therapy
Hematologic Neoplasms
Immune System
Immunity
Neoplasms
Drug Therapy
Survival
Therapeutics

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

@article{84076dec94ab483c97f62a5a09e807b1,
title = "Antigen-specific allogeneic immunotherapy--selective augmentation of GVL effects",
abstract = "Advancement of chemotherapeutic agents and introduction of molecular-targeted therapy have been improving the prognosis of malignant tumors. However, allogeneic hematopoietic cell transplantation (allo-HCT) still remains the sole curative therapy against chemotherapy-resistant hematological malignancies. Once it was found that full engraftment of donor's immune cells could bring sufficient graft-versus-leukemia/lymphoma(GVL)effects, reduced intensity preconditioning regimens that focus only on suppression of the recipient's immune system so as to allow donor graft engraftment have been introduced into clinics. This has expanded the number of patients eligible for allo-HCT, including elderly patients. Nevertheless, overall survival of patients with high-risk malignancies has not been sufficiently improved. Simple enhancement of donor-derived immunity would result in the increased risk of graft-versus-host disease (GVHD). Here, current and future strategies to selectively enhance GVL effects without inducing detrimental GVHD will be discussed in parallel with their background information and basic concepts.",
author = "Yoshiki Akatsuka",
year = "2008",
month = "1",
day = "1",
language = "English",
volume = "35",
pages = "713--719",
journal = "Japanese Journal of Cancer and Chemotherapy",
issn = "0385-0684",
publisher = "Japanese Journal of Cancer and Chemotherapy Publishers Inc.",
number = "5",

}

Antigen-specific allogeneic immunotherapy--selective augmentation of GVL effects. / Akatsuka, Yoshiki.

In: Gan to kagaku ryoho. Cancer & chemotherapy, Vol. 35, No. 5, 01.01.2008, p. 713-719.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Antigen-specific allogeneic immunotherapy--selective augmentation of GVL effects

AU - Akatsuka, Yoshiki

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Advancement of chemotherapeutic agents and introduction of molecular-targeted therapy have been improving the prognosis of malignant tumors. However, allogeneic hematopoietic cell transplantation (allo-HCT) still remains the sole curative therapy against chemotherapy-resistant hematological malignancies. Once it was found that full engraftment of donor's immune cells could bring sufficient graft-versus-leukemia/lymphoma(GVL)effects, reduced intensity preconditioning regimens that focus only on suppression of the recipient's immune system so as to allow donor graft engraftment have been introduced into clinics. This has expanded the number of patients eligible for allo-HCT, including elderly patients. Nevertheless, overall survival of patients with high-risk malignancies has not been sufficiently improved. Simple enhancement of donor-derived immunity would result in the increased risk of graft-versus-host disease (GVHD). Here, current and future strategies to selectively enhance GVL effects without inducing detrimental GVHD will be discussed in parallel with their background information and basic concepts.

AB - Advancement of chemotherapeutic agents and introduction of molecular-targeted therapy have been improving the prognosis of malignant tumors. However, allogeneic hematopoietic cell transplantation (allo-HCT) still remains the sole curative therapy against chemotherapy-resistant hematological malignancies. Once it was found that full engraftment of donor's immune cells could bring sufficient graft-versus-leukemia/lymphoma(GVL)effects, reduced intensity preconditioning regimens that focus only on suppression of the recipient's immune system so as to allow donor graft engraftment have been introduced into clinics. This has expanded the number of patients eligible for allo-HCT, including elderly patients. Nevertheless, overall survival of patients with high-risk malignancies has not been sufficiently improved. Simple enhancement of donor-derived immunity would result in the increased risk of graft-versus-host disease (GVHD). Here, current and future strategies to selectively enhance GVL effects without inducing detrimental GVHD will be discussed in parallel with their background information and basic concepts.

UR - http://www.scopus.com/inward/record.url?scp=45549092409&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45549092409&partnerID=8YFLogxK

M3 - Review article

C2 - 18487905

AN - SCOPUS:45549092409

VL - 35

SP - 713

EP - 719

JO - Japanese Journal of Cancer and Chemotherapy

JF - Japanese Journal of Cancer and Chemotherapy

SN - 0385-0684

IS - 5

ER -